Condition: Geographic Atrophy (GA) · Sponsor: Regeneron Pharmaceuticals
This study is researching an experimental drug called pozelimab (called "study drug"). The study is focused on people with a condition where certain parts of the eye's retina stop working over time, which can make it harder to see. This is called geographic atrophy (GA). The aim of the study is to see how safe and tolerable the study drug is when used as an injection in the eye. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood and the fluid in the eye at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
This description comes directly from the study's public registry record.
Clinical Trials Administrator · 844-734-6643 · clinicaltrials@regeneron.com
Always discuss trial participation with your own doctor first.
| Colorado Retina Associates | Lakewood, Colorado, United States | Recruiting |
| Ophthalmic Consultants of Boston | East Weymouth, Massachusetts, United States | Recruiting |
| Austin Retina Associates | Austin, Texas, United States | Recruiting |
| Retina Foundation of the Southwest | Dallas, Texas, United States | Recruiting |
| Retina Consultants Texas | The Woodlands, Texas, United States | Recruiting |
| Arensia Exploratory Medicine at the Research Institute of Clinical Medicine | Tbilisi, Georgia | Recruiting |
| ARENSIA Clinics SRL | Bucharest, Romania | Recruiting |
| Arensia Exploratory Medicine Clinic at Country Hospital Cluj-Napoca | Cluj-Napoca, Romania | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07230834